Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple
Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin
reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI)
antidepressants over 16 weeks as add-on to fingolimod treatment. It is designed to evaluate
the safety and tolerability of this combination in this patient population based on an
immunomodulatory treatment with fingolimod.